Companies
Every applicant and authorisation holder that holds or has held an orphan drug status in Switzerland.
#
A
- AbbVie AG9
- Accord Healthcare AG1
- Actelion Pharmaceuticals Ltd1
- ADIENNE SA8
- ADVANCED ACCELERATOR APPLICATIONS (SWITZERLAND) SA1
- Advanz Pharma Specialty Medicine Switzerland GmbH1
- Ageronix SA1
- AL-S Pharma AG1
- Alexion Pharma GmbH21
- Alfasigma Schweiz AG2
- Alnylam Switzerland GmbH4
- Amgen Switzerland AG8
- Amicus Therapeutics Switzerland GmbH3
- argenx Switzerland SA3
- Arog Pharmaceuticals Europe Ltd, c/o TMF Groupe1
- Ascendis Pharma Switzerland GmbH2
- Astellas Pharma AG2
- AstraZeneca AG10
- Atlantic Healthcare plc1
B
C
- CD PHARMA (SUISSE) SA1
- Celgene International Sàrl3
- Centre hospitalier universitaire vaudois (CHUV)1
- Cheplapharm Schweiz GmbH1
- Chiesi Farmaceutici SpA3
- Chiesi SA6
- Clinigen Group plc Pitcairn House, c/o Proreo Pharma1
- Clinuvel AG4
- Cosan GmbH1
- CPS Cito Pharma Services GmbH1
- CSL Behring AG8
- CSL Behring Lengnau AG2
- Curatis AG3
D
E
F
G
H
I
J
K
L
M
N
O
P
R
S
- Sandoz Pharmaceuticals AG4
- Sanofi-Aventis (Suisse) SA13
- Santen SA1
- Santhera Pharmaceuticals (Schweiz) AG1
- Schircks Laboratories1
- Schweizerisches Tropen- und Public Health-Institut (Swiss TPH)1
- Servier (Suisse) SA7
- Somagenetix AG1
- Spirig HealthCare AG1
- Stemline Therapeutics Switzerland GmbH3
- Swedish Orphan Biovitrum AG10
T
U
V
W
Y
Z
No matches
No entry matches this term. Check the spelling, or search for the active substance instead of the brand name.
Frequently asked questions
How does a medicine obtain orphan drug status in Switzerland?
On application to Swissmedic. It requires a life-threatening or chronically debilitating disease affecting no more than 5 in 10,000 people in Switzerland, or an existing recognition in a country with comparable medicinal product control (Art. 4 para. 1 let. a decies TPA, Art. 4 TPLO).
What does the status actually give you?
The simplified authorisation procedure (Art. 14 para. 1 let. f TPA), priority assessment, a waiver of the flat-rate fee for the new authorisation application and, on request, 15 years of document protection (Art. 11b para. 4 TPA). There is no market exclusivity as in the EU.
How current is the data on Companies?
Swissmedic publishes the list of medicinal products with orphan drug status under Art. 7 TPLO and updates it monthly. The date of the data set processed here is shown at the foot of every page.
Bring your orphan drug to Switzerland
You can enquire about orphan drug status, authorisation and reimbursement in Switzerland. Any specialist service and its scope are agreed separately with the external partner.
- Public Swissmedic data
- Four language versions